Slide 1: Vidofludimus Calcium in Progressive MS
OSITIN in Progressive NASDAQ: IMUX | May 2025 | CONFIDENTIAL
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 216 of the Securities
Slide 3: Vidofludimus Calcium: Clinical Trials Overview in Multiple Sclerosis (MS)
Vidofludimus Calcium: Clinical Trials Overview in Multiple Sclerosis (MS) ENSURE-2 | RELAPSING MS Phase 3 Fully enrolled, n=1100 patients Top-Line Data Expected End of 2026 pooled for both ENSURE-1 | RELAPSING MS ENSURE tale Phase 3 Fully enrolled, n=1121 patients PROGRESSIVE MS CALLIPER 2 Redu Phas
Slide 4: Top-Line Data Phase 2 CALLIPER Trial: Clinical Endpoints
Top-Line Data Phase 2 CALLIPER Trial Clinical Endpoints
Slide 5: Vidofludimus Calcium Reduced Time to 24wCDW in Overall Study Population and All Subtypes
Vidofludimus Calcium Reduced Time to 24wCDW in Overall Study Population and All Subtypes Compared to Placebo Overall CALLIPER PPMS naSPMS aSPMS Patient Population (N=467) (N=152) (N=268) (N=47) HR (Kaplan Meier) 0.759 0.675 0.809 0.663 95 % Cl [0.477, 1.206] [0.324, 1.406] [0.418, 1.565] [0.315, 2.9
Slide 6: Time to 24-Week Confirmed Disability Worsening (Based on EDSS)
Time to 24-Week Confirmed Disability Worsening (Based on EDSS) All Patients — All Disease Subtypes Combined — Kaplan-Meier Analysis of 24wCDW Time to 24wCDW x Relative Risk Reduction 0.5: 04 0.3 0.2 Propotion Free of 24wCDW Strata —— IMU-838 Placebo 48 72 Time Since Randomization (weeks) Overall CAL
Slide 7: Time to 24-Week Confirmed Disability Worsening (Based on EDSS)
Time to 24-Week Confirmed Disability Worsening (Based on EDSS) PPMS Subpopulation — Kaplan-Meier Analysis of 24wCDW Strata —= IMU-838 Placebo roy Time to 24wCDW 0s. Relative Risk Reduction O4 PPMS Patient z Population 8 g = 03 HR (Kaplan-Meier) 0.675 © 02 RRR 32.5% § 95% Cl [0.324, 1.406] 0.1 p-valu
Slide 8: Comparison CALLIPER Versus ORATORIO Trials in PPMS Population
Comparison CALLIPER Versus ORATORIO Trials in PPMS Population ORATORIO* CALLIPER (N=732) (N=152) Mean Age (Years) 44.6 474 Female (N,%) 361 (49.3%) 93 (61.1%) EDSS - Mean 4.7 4.9 EDSS - Median 45 45 Gd+ Lesions at Baseline MRI (N,%) 26.6% 17.8% a = = 8 | © immunic, inc. | May/27/2025 & Immunic
Slide 9: Vidofludimus Calcium Substantially Reduced 24wCDW in Patients Without Gd+ Lesions at Baseline
Vidofludimus Calcium Substantially Reduced 24wCDW in Patients Without Gd+ Lesions at Baseline Time to 24wCDW With No Evidence of Gd+ Lesions at Baseline Group Numbenot HR 95 % Cl p-value RRR tt24wCDW Patients All Patients 391 0.662 (0.393, 1.114] 0.120 33.8% PPMS 125 0.654 0.293, 1.460] 0.300 34.6%
Slide 10: Vidofludimus Calcium Substantially Reduced 24wCDW in Patients Without Gd+ Lesions at Baseline
Vidofludimus Calcium Substantially Reduced 24wCDW in Patients Without Gd+ Lesions at Baseline 0.5. id Patient Population 2 7 Without Gd+ Lesions 8 at Baseline = & 03 ES HR (Kaplan-Meier) 0.662 § 02 RRR 33.8% e 95% Cl [0.393, 1.114] 01 P-value 0.120 0 =o N 391 0 24 48 72 96 120 Strata == IMU-838 Plac
Slide 11: Vidofludimus Calcium Substantially Reduced 24wCDW in PPMS Patients Without Gd+ Lesions
Vidofludimus Calcium Substantially Reduced 24wCDW in PPMS Patients Without Gd+ Lesions at Baseline Strata —— IMU-838 Placebo él Time to 24wCDW. 05 N Relative Risk Reduction PPMS Patient 04 Population Without a Gd+ Lesions at Ed Baseline 8 03 o HR (Kaplan-Meier) 0.654 & 02 RRR 34.6% & 95% Cl [0.293,
Slide 12: CALLIPER successfully demonstrated the neuroprotective potential of vidofludimus calcium in PMS patients
CALLIPER successfully demonstrated the neuroprotective potential of vidofludimus calcium in PMS patients Clinically meaningful risk reduction of confirmed disability worsening of 24% in overall PMS population and even more prominent 33% reduction in PPMS population
Slide 13: Magnetic Resonance Imaging (MRI) Endpoints
Magnetic Resonance Imaging (MRI) Endpoints I), f Top-Line Data Phase 2 CALLIPER Trial YY —
Slide 14: Vidofludimus Calcium Substantially Lowered Volume of New/Enlarging T2 Lesions Compared to Placebo
Vidofludimus Calcium Substantially Lowered Volume of New/Enlarging T2 Lesions Compared to Placebo = Change of T2 lesion volume (cm?) gets steadily worse compared to baseline in placebo ore patients while remaining stable in 3 vidofludimus calcium patients (p=0.016) & = Volume change different betwee
Slide 15: Brain Atrophy Endpoints Consistently Demonstrated Beneficial Effect of Vidofludimus Calcium
Brain Atrophy Endpoints Consistently Demonstrated Beneficial Effect of Vidofludimus Calcium Compared to Placebo CChange in Whole Brain Volume - All Patients Re-Baselined at 6 Months eVidottudimus Caleium —o-Paceto = Modest benefit on exploratory primary MRI endpoint: decreased annualized rate of who
Slide 16: Top-Line Data Phase 2 CALLIPER Trial: Conclusions and Outlook
Top-Line Data Phase 2 CALLIPER Trial Conclusions and Outlook _
Slide 17: Positive Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive MS
17 | © immunic, inc. | May/27/2025 | Ln | Positive Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Clinically meaningful risk reduction of 24wCDW by 24% in overall study population; even more prominent 33% reduction in high unmet need population of PPMS Rem
Slide 18: Thank You!
Thank You! Jessica Breu Vice President Investor Relations & Communications G Phone: +1-332-255-9819 ©& Email: ir@imux.com © Web: www.imux.com 18 | © immunic, inc. | May/27/2025 Immunic, Inc. 1200 Avenue of the Americas New York City, NY 10036 USA Immunic AG Lochhamer Schlag 21 82166 Grafelfing (Muni
Slide 19: Top-Line Data Phase 2 CALLIPER Trial: Back-up
A > —_ Top-Line Data Phase 2 CALLIPER Trial Back-up - ‘ ——
Slide 20: Time to 24-Week Confirmed Disability Worsening (Based on EDSS)
Time to 24-Week Confirmed Disability Worsening (Based on EDSS) naSPMS Subpopulation — Kaplan-Meier Analysis of 24wCDW Strata —— IMU-838 Placebo Ql Time to 24wCDW 05 Relative Risk Reduction 04 naSPMS Patient z Population 8 2 BR 03 HR (Kaplan-Meier) 0.809 © 02 RRR 19.1% 95% Cl [0.418, 1.565] 0.1 —— =
Slide 21: Time to 24-Week Confirmed Disability Worsening (Based on EDSS)
Time to 24-Week Confirmed Disability Worsening (Based on EDSS) aSPMS Subpopulation — Kaplan-Meier Analysis of 24wCDW Strata == IMU-838 Placebo Time to 24wCDW 05 Relative Risk Reduction 04 aSPMS Patient z Population g BR 03 HR (Kaplan-Meier) 0.663 ic 02 RRR 33.7% 95% Cl (0.315, 2.974] 01 —_ | p-value
Slide 22: Vidofludimus Calcium Significantly Reduced EDSS Increase from Baseline Compared with Placebo
Vidofludimus Calcium Significantly Reduced EDSS Increase from Baseline Compared with Placebo MMRM Analysis (All Patients): Change from Baseline in EDSS score 0.38 —e- Vidofludimus Calcium Placebo 03 * Statistically significant (p<0.05) ** Statistically significant (p<0.01) 0.25 02 0.18 Ls Mean of ED